Sep 26, 2022 3:14:56 PM / by Olink posted in Wider proteomics studies, Multiomics, Population based studies
Speakers:
Prof. Sir Rory Collins, Head of Nuffield Department of Population Health, University of Oxford,
Prof. Zhenming Chen, Richard Peto Chair in Epidemiology, University of Oxford and
Dr. Benjamin Sun Associate Scientific Director, Translational Biology at Biogen.
Dec 3, 2021 10:04:35 AM / by Olink posted in Oncology, Multiomics, Clinical research, Population based studies
Speakers: Dr. Anders Mälarstig Director of Target Sciences Pfizer Worldwide Research and Development
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.